| Item Type | Name |
|
Concept
|
Lymphoma, Follicular
|
|
Concept
|
Lymphoma
|
|
Concept
|
Lymphoma, Mantle-Cell
|
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Academic Article
|
Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.
|
|
Academic Article
|
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
|
|
Academic Article
|
A drug safety evaluation of rituximab and risk of hepatitis B.
|
|
Academic Article
|
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
|
|
Academic Article
|
Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.
|
|
Academic Article
|
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
|
|
Academic Article
|
Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
|
|
Academic Article
|
Diagnostic Evaluation in Primary CNS Lymphoma.
|
|
Academic Article
|
Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
|
|
Academic Article
|
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
|
|
Academic Article
|
Double hit and double expressors in lymphoma: Definition and treatment.
|
|
Academic Article
|
Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma.
|
|
Academic Article
|
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.
|
|
Academic Article
|
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
|
|
Academic Article
|
Advances in CAR T-Cell Therapy for Aggressive B-NHL.
|
|
Academic Article
|
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.
|
|
Academic Article
|
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
|
|
Academic Article
|
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
|
|
Academic Article
|
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
|
|
Academic Article
|
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
|
|
Academic Article
|
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
|
|
Academic Article
|
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
|
|
Academic Article
|
Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators.
|
|
Academic Article
|
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
|
|
Academic Article
|
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
|
|
Academic Article
|
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
|
|
Academic Article
|
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
|
|
Academic Article
|
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
|
|
Academic Article
|
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.
|
|
Academic Article
|
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
|
|
Academic Article
|
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
|
|
Academic Article
|
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
|
|
Academic Article
|
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
|
|
Academic Article
|
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
|
|
Academic Article
|
Infectious complications of car T-cell therapy: A longitudinal risk model.
|
|
Academic Article
|
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
|
|
Academic Article
|
If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary.
|
|
Academic Article
|
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
|